A Descriptive Comparative Analysis of Safety Concerns Outlaid in the Risk Management Plans of the European Union and Japan
Pharmacoepidemiology and Drug Safety · 2025
DOI: 10.1002/pds.70097 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Teruyuki Honda und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine (Pharmaceutical Medicine), Graduate School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan. Hauptthemen laut MEDLINE: Risk Management, Drug-Related Side Effects and Adverse Reactions. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Purpose
This study aimed to obtain a better understanding of the characteristics of the risk management plans (RMP) and the background regulatory policies governing them, in the European Union (EU) and Japan. This was done by descriptively comparing the safety concerns (SCs) listed in the RMP and examining their relationships with product labeling.
Methods
Information regarding SCs was collected from the published RMP of both the EU and Japan for the targeted products—all of which were commonly approved in both regions. The concordance rate of the SCs for each product between the EU‐ and Japan‐RMP was calculated. The warning information for each product was collected from the product labeling, summary of product characteristics for the EU, and package insert for Japan, and compared with the SCs listed in the corresponding RMP.
Results
A total of 259 products that were approved for sale in both the EU and Japan (1998–2023), for which RMP were available in both regions, were analyzed. While 51.0% of the SCs labeled as important identified risks (IIRs) in the EU‐RMP were concordant with those in the Japan‐RMP, 20.4% of the SCs listed as IIRs in the Japan‐RMP were concordant with those in the EU‐RMP. The concordance rate between the SCs identified as IIRs and the warning information was 18.6% for the EU‐RMP and 88.4% for the Japan‐RMP.
Conclusions
The low SC concordance rate between the EU‐ and Japan‐RMP indicates a different approach to selecting RMP SCs by the two regulatory authorities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Medicine (Pharmaceutical Medicine), Graduate School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan.
- Pharmacovigilance, MSD-K.K, Tokyo, Japan.
ORCID-Profile: Teruyuki Honda
Zitieren
APA
Honda, T., & Narukawa, M. (2025). A Descriptive Comparative Analysis of Safety Concerns Outlaid in the Risk Management Plans of the European Union and Japan. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70097
Vancouver
Honda T, Narukawa M. A Descriptive Comparative Analysis of Safety Concerns Outlaid in the Risk Management Plans of the European Union and Japan. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70097
BibTeX
@article{Honda2025,
author = {Honda, Teruyuki and Narukawa, Mamoru},
title = {A Descriptive Comparative Analysis of Safety Concerns Outlaid in the Risk Management Plans of the European Union and Japan},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
doi = {10.1002/pds.70097}
}
EUVIMED